LXR

FASHIONPHILE Acquires LXRandCo, Inc. Brand

Retrieved on: 
Friday, November 10, 2023
Acquisition, SAN, LXR, Prada, Marcus (name), Neiman Marcus, Bankruptcy and Insolvency Act, System, Chanel, Partnership, Bankruptcy, Retail, B2B

SAN DIEGO, Nov. 10, 2023 /PRNewswire/ -- FASHIONPHILE, the leading resale e-commerce platform in pre-owned, ultra-luxury accessories, announced today that it has acquired the inventory, intellectual property assets, including domains, and other intangible assets of LXR Luxury Products International Inc., Groupe Global LXR Inc., and LXR Canada Inc. (collectively, the "Subject Companies"), which are the operating subsidiaries of LXRandCO, Inc. ("LXR"), the Montreal-based omnichannel retailer of authenticated, pre-owned luxury accessories. Earlier this month, the Subject Companies filed a notice of intention to make a proposal under the Bankruptcy and Insolvency Act (Canada).

Key Points: 
  • Earlier this month, the Subject Companies filed a notice of intention to make a proposal under the Bankruptcy and Insolvency Act (Canada).
  • This brand acquisition will facilitate FASHIONPHILE's ability to diversify its selling channels beyond direct-to-consumer, elevated circular retail experiences and clienteling and expand into B2B wholesale and new omnichannel operations.
  • The transaction follows FASHIONPHILE entering a partnership with the Neiman Marcus Group in 2019 to become the luxury specialty retailer's exclusive recommerce partner.
  • FASHIONPHILE has since opened 10 Selling Studio locations inside Neiman Marcus stores across the country to provide a unique, first-of-its-kind circular service and elevate the luxury resale-retail experience.

OrsoBio Announces $60M Series A Financing to Advance Metabolic Portfolio for the Treatment of Obesity and Associated Disorders

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Eli Lilly and Company, IND, NYSE, LXR, DSM-IV codes, Obesity, LLY, MD, Doctor of Philosophy, Agonal respiration, Commercialization, NASH, Cancer, ACMSD, Series, Patient, Pharmaceutical industry, Nursing, Saṃsāra

The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.

Key Points: 
  • The financing, which will support the advancement of OrsoBio’s obesity-focused portfolio, was co-led by Longitude Capital and Enavate Sciences.
  • OrsoBio will utilize the Series A funding to advance the development of its innovative portfolio of four programs focused on obesity and associated metabolic disorders.
  • ACMSD inhibitor (aminocarboxymuconate semialdehyde decarboxylase inhibitor): Selection of a development candidate for potential treatment of metabolic and inflammatory liver and kidney disorders and advancement of IND-enabling activities.
  • “We are grateful for the continued trust in our team and commitment to our mission to improve clinical outcomes in patients with obesity and associated metabolic disorders.

OrsoBio to Present Phase 1 Data for the Liver-Targeted LXR Inverse Agonist TLC-2716 in Development for Severe Hypertriglyceridemia and NASH at AHA’s Scientific Sessions 2023

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, C3, Plasma, De novo, LXR, DSM-IV codes, Liver, MD, Safety, Apolipoprotein B, American Heart, Lipid, Oral, NASH, LDL, PK, Liver X receptor, Triglyceride, Liver disease, AE, Patient, Fatty liver disease, Cholesterol, Hypertriglyceridemia, Pharmaceutical industry, Pharmacokinetics, ANGPTL3

TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • TLC-2716 is in clinical development as a potential treatment for severe hypertriglyceridemia (SHTG) and nonalcoholic steatohepatitis (NASH).
  • In data presented at AASLD’s The Liver Meeting®, TLC-2716 demonstrated highly potent and consistent improvements in plasma triglycerides and cholesterol and hepatic steatosis in preclinical models.
  • Notably, due to active hepatic uptake and limited systemic exposures, TLC-2716 did not adversely affect peripheral reverse cholesterol transport.
  • The results support the ongoing development of TLC-2716 in patients with metabolic disorders including SHTG and NASH.

BRAEMAR HOTELS & RESORTS UNVEILS THE CAMEO BEVERLY HILLS, A REBRANDING OF THE MR. C BEVERLY HILLS, JOINING THE HILTON FAMILY OF BRANDS

Retrieved on: 
Wednesday, August 2, 2023
Braemar, Partnership, REIT, Flamingo Resort, Inc. v. United States, Hilton, History, BHR, Collection, The Biltmore Mayfair, LXR Hotels & Resorts, Remington, Rodeo Drive, LXR, Hilton Worldwide, NYSE, Hotel

DALLAS, Aug. 1, 2023 /PRNewswire/ -- Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced the rebranding and planned conversion of its Mr. C Beverly Hills ("Mr. C") in Los Angeles, California to the Cameo Beverly Hills.

Key Points: 
  • DALLAS, Aug. 1, 2023 /PRNewswire/ -- Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced the rebranding and planned conversion of its Mr. C Beverly Hills ("Mr. C") in Los Angeles, California to the Cameo Beverly Hills.
  • Beginning August 4, 2023, Cameo Beverly Hills will be available for booking on Hilton's website at hilton.com and join Hilton Honors, Hilton's award-winning guest loyalty program.
  • Following an extensive renovation, which is expected to be completed by the end of 2025, the hotel will join LXR Hotels & Resorts ("LXR").
  • Braemar Hotels & Resorts is a real estate investment trust (REIT) focused on investing in luxury hotels and resorts.

Inspirna Announces Interim Data from Phase 1b/2 Study of Abequolixron (RGX-104) in Relapsed or Refractory Lung Cancer

Retrieved on: 
Thursday, January 5, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Lung cancer, LXR, Clinical trial, PRS, PD, Squamous cell carcinoma, BID, Docetaxel, Diarrhea, Division, Principal investigator, PR, CNS, Nausea, Patient, Bristol Myers Squibb, Ipilimumab, Bill of rights, RECIST, Weight loss, SCLC, Fatigue, Therapy, Large-cell lung carcinoma, Appetite, Neutropenia, MDSC, CTL, Fox Chase Cancer Center, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, SD, APOE, NSCLC, Pharmaceutical industry

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today interim data from its ongoing Phase 1b/2 clinical trial of abequolixron in patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).

Key Points: 
  • Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule cancer therapeutics, announced today interim data from its ongoing Phase 1b/2 clinical trial of abequolixron in patients with non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).
  • Abequolixron is currently being evaluated in a Phase 1b/2 clinical trial in combination with docetaxel in second- or third-line (2/3L) NSCLC as well as second-line (2L) SCLC.
  • The primary objectives of the study include characterizing the safety profile and the antitumor activity of the abequolixron and docetaxel combination.
  • In addition, this Phase 1b/2 study includes an ongoing expansion arm of abequolixron in combination with Yervoy (ipilimumab) in second- or third-line endometrial cancer as part of a clinical collaboration with Bristol Myers Squibb.

Resorts World Las Vegas Becomes 1st Resort to Launch Next Generation of Cashless

Retrieved on: 
Wednesday, November 30, 2022
Consumer Electronics, Technology, Tourist Attractions, Apps, Applications, Lodging, Destinations, Travel, Electronic Commerce, Electronic Games, Digital Cash Management, Digital Assets, Casino, Gaming, Vacation, Payments, Software, Entertainment, History, United Kingdom, Naval EOD Technology Division, Multimedia, Laboratory, Partnership, Nevada Gaming Commission, Resorts World, LXR, ID, Sport, Collection, Genting Group, Forbes Travel Guide, Resort, Casino, Sightline

Resorts World Las Vegas and Sightline today announced the launch of 2nd generation cashless technology ushering in an experience with unprecedented functionality, greatly enhancing the omnichannel consumer journey.

Key Points: 
  • Resorts World Las Vegas and Sightline today announced the launch of 2nd generation cashless technology ushering in an experience with unprecedented functionality, greatly enhancing the omnichannel consumer journey.
  • Resorts World Las Vegas is the first casino in Nevada to enable its guests to enroll, verify, and fund from anywhere around the world in as little as a few minutes.
  • In partnership with Hilton, Resorts World Las Vegas integrates three of Hiltons premium brands into its resort campus, including Las Vegas Hilton, the resorts full-service brand; Conrad Las Vegas, Hiltons lifestyle luxury brand; and LXR, Hiltons network of independent luxury properties, which operates as Crockfords Las Vegas, Gentings internationally renowned ultra-luxury brand.
  • Resorts World Las Vegas is Sharecare Health Security VERIFIED with Forbes Travel Guide, a verification that ensures the resort has appropriate health safety procedures in place.

OrsoBio Announces Presentation of Five Abstracts at AASLD’s The Liver Meeting® 2022 Highlighting Programs for Severe Metabolic Disorders

Retrieved on: 
Thursday, November 3, 2022
Health, Infectious Diseases, Diabetes, Clinical Trials, Pharmaceutical, Biotechnology, Doctor of Philosophy, Abstract (summary), Associate, Research, Phase 1, 2021 Essex County Council election, Weight loss, Liver, Custom, Lipogenesis, Cincinnati, Respiration (physiology), Mouse, NASH, Safety, Pharmacokinetics, AMPK, IPSC, Non-alcoholic fatty liver disease, Northwest Hospital & Medical Center, Lipotoxicity, Liver X receptor, Patient, Institute of Liver and Biliary Sciences, TCA, AASLD, Pediatrics, Translation, Hepatocyte, Oxidative stress, Plasma, Dyslipidemia, Gilead Sciences, GCKR, De novo, DNL, Foundation, LDL, Tryptophan, Fatty liver disease, Center, Acquired generalized lipodystrophy, Lipid metabolism, Gene, Insulin resistance, Primate, ABCA1, MD, ABCG1, LXR, Pharmaceutical industry, Medical device, Vaccine, Dietary supplement, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced the presentation of five abstracts from the companys programs at AASLDs The Liver Meeting from November 4-8.
  • There remains tremendous unmet medical need for patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio.
  • I am truly excited about translating the data on OrsoBios compounds in HLOs derived from genetic subsets of patients to clinical studies in patients with severe metabolic disorders.
  • The following abstracts will be presented as poster presentations at The Liver Meeting, in Washington, D.C., November 4-8, 2022.

OrsoBio Announces Acquisition of LXR Inverse Agonist Program for Treatment of Severe Dyslipidemias from Phenex Pharmaceuticals

Retrieved on: 
Wednesday, November 2, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Pharmacology, Entrepreneurship, Liver, MD, Lipogenesis, Plasma, Steatosis, ABCG1, Acquisition, Mouse, Liver disease, Hypertriglyceridemia, Lipoprotein, IPSC, Respiration (physiology), Institute of Liver and Biliary Sciences, NASH, Fatty liver disease, Foundation, DNL, Lipid metabolism, ABCA1, LXR, Patient, GCKR, De novo, Acquired generalized lipodystrophy, Gilead Sciences, Gene, Dyslipidemia, Cholesterol, Abstract (summary), Pharmaceutical industry, Gum arabic, Dietary supplement, Doctor of Philosophy, Liver X receptor, Rail profile

OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.

Key Points: 
  • OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property.
  • Our Phase 1 study is progressing well, and we look forward to the continued development of TLC-2716 for the treatment of severe dyslipidemias in 2023.
  • I am truly excited that OrsoBio is progressing TLC-2716 into the clinic to unlock the potential of this first-in-class compound for patients with severe dyslipidemias.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

OrsoBio Launches to Develop Novel Therapies for Patients with Severe Metabolic Disorders

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Liver, MD, HLO, CEO, Stanford University, American Association for the Study of Liver Diseases, Doctor of Philosophy, Aminocarboxymuconate-semialdehyde decarboxylase, Liver X receptor, Hypertriglyceridemia, Partner, Industry, Intellectual property, Respiration (physiology), Northwest Hospital & Medical Center, American Association, Institute of Liver and Biliary Sciences, NASH, Cincinnati, Fatty liver disease, Metabolism, LXR, NAD, Patient, Therapy, Gilead Sciences, Lipodystrophy, Tryptophan, Dyslipidemia, Phase 1, Diabetes, Yale University, Association, Pharmaceutical industry, Medical imaging, DRS, Shionogi, Astellas Pharma, Immunology

OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).

Key Points: 
  • OrsoBio has initiated preclinical and clinical activities to support advancement of these compounds for the treatment of patients with severe metabolic disorders, including diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis (NASH).
  • Our programs address the root causes of metabolic dysregulation in patients with severe metabolic disorders, said Mani Subramanian, MD, PhD, Founder and CEO of OrsoBio.
  • The OrsoBio approach of targeting multiple fundamental aspects of cellular energetics addresses large unmet patient need in severe metabolic diseases.
  • OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis.

RESORTS WORLD LAS VEGAS AND THE BORING COMPANY OFFICIALLY OPEN PROPERTY'S PASSENGER STATION, PROVIDING DIRECT ACCESS TO THE LAS VEGAS CONVENTION CENTER

Retrieved on: 
Thursday, June 30, 2022
Las Vegas Convention and Visitors Authority, LED, Resorts World, View, LinkedIn, Transport, CEO, Travel, Las Vegas Convention Center, Collection, Resorts World Las Vegas, Genting Group, The Boring Company, Forbes Travel Guide, United Kingdom, Partnership, Technology, Tesla, LVCC, Nevada Gaming Commission, LXR, Instagram, Twitter, Intention, Multimedia, LVCVA, Hotel, Resort, Genting, Facebook

LAS VEGAS, June 30, 2022 /PRNewswire/ -- Today, Resorts World Las Vegas unveiled its Las Vegas Convention Center Loop passenger station, providing direct underground access to the Las Vegas Convention Center (LVCC)inan enjoyable, efficient and environmentally friendly way inminutes inall-electric Teslas.Resorts WorldLas Vegasis now also poised to connect to the expanded Vegas Loop system when development efforts move forward on the proposedinnovative transportation system.

Key Points: 
  • LAS VEGAS, June 30, 2022 /PRNewswire/ -- Today, Resorts World Las Vegas unveiled its Las Vegas Convention Center Loop passenger station, providing direct underground access to the Las Vegas Convention Center (LVCC)inan enjoyable, efficient and environmentally friendly way inminutes inall-electric Teslas.Resorts WorldLas Vegasis now also poised to connect to the expanded Vegas Loop system when development efforts move forward on the proposedinnovative transportation system.
  • The Vegas Loop will be constructed in phases that include the Resorts World Las Vegas passenger station, the LVCC Loop and future service extensions along the Strip and Downtown Las Vegas.
  • "Today marks a monumental moment not only for our resort, but for Las Vegas," said Scott Sibella, president of Resorts World Las Vegas.
  • Resorts World Las Vegas strives to transform the way people experience Las Vegas, and this offering does just that.